Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

NCT00612222 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

NIH

Sponsor class

Stopped The study was terminated due to low accrual.

Conditions

Metastatic Melanoma
Skin Cancer

Interventions

BIOLOGICAL: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
BIOLOGICAL: ALVAC MART-1 Vaccine
BIOLOGICAL: aldesleukin
DRUG: cyclophosphamide
DRUG: fludarabine phosphate

Sponsor

National Cancer Institute (NCI)